Search
ranibizumab (Lucentis, Byooviz)
Ophthalmics: Lucentis; Biosimilar: Byooviz
Indications:
- macular degeneration [1]
- diabetic macular edema (diabetic retinopathy) [2]
- visual impairment due to choroidal neovascularisation secondary to pathological myopia (NICE, see NGC)
Dosage:
- intavitreal injection of 0.3-0.5 mg monthly
Adverse effects:
- conjunctival hemorrhage
- eye pain
- floaters
- increased intra-ocular pressure [5]
- ophthalmitis
- retinal detachment [5]
Mechanism of action:
- angiogenesis inhibitor, binds to VEGF
Notes:
- according to the Washington Post, this is the same drug as bevacizumab (Avastin) both produced by Genentech [3]
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
Specific
ranibizumab ophthalmic (Lucentis, Byooviz)
General
vascular endothelial growth factor (VEGF) inhibitor
antineoplastic monoclonal antibody
References
- Rosenfeld PJ et al
Ranibizumab for neovascular age-related macular degeneration
N Engl J Med 2006, 355:1419
PMID: 17021318
- Brown DM et al
Ranibizumab versus verteporfin for neovascular age-related
macular degeneration.
N Engl J Med 2006, 355:1432
PMID: 17021319
- Steinbrook R.
The price of sight - Ranibizumab, bevacizumab, and the
treatment of macular degeneration.
N Engl J Med 2006, 355:1409
PMID: 17021315
- Stone EM.
A very effective treatment for neovascular macular
degeneration
N Engl J Med 2006, 355:1493
PMID: 17021326
- FDA News Release: Aug. 10, 2012
FDA approves Lucentis to treat diabetic macular edema
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315130.htm
- Kliff S
This $2,000 drug says everything about our messed up health-
care system.
Washington Post Dec 9, 2013
http://www.washingtonpost.com/blogs/wonkblog/wp/2013/12/09/this-2000-drug-says-everything-about-our-messed-up-health-care-system/
- Bressler NM, Doan QV, Varma R et al
Estimated cases of legal blindness and visual impairment
avoided using ranibizumab for choroidal neovascularization:
non-Hispanic white population in the United States with age-
related macular degeneration.
Arch Ophthalmol. 2011 Jun;129(6):709-17.
PMID: 21670337
- FDA News Release. February 6, 2015
FDA approves Lucentis to treat diabetic retinopathy in patients
with diabetic macular edema.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm433392.htm
- Bressler NM, Kim T, Oh I et al
Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product
Lucentis and Association With Efficacy, Safety, and PharmacokineticsA Post Hoc
Analysis of a Phase 3 Randomized Clinical Trial.
JAMA Ophthalmol. 2023;141(2):117-127.
PMID: 36520462 PMCID: PMC9857301 Free PMC article
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2799737